Controversies in the pathological assessment of colorectal cancer

World Journal of Gastroenterology

Volumn , Issue 29, 2014, Pages 9850-9861

  Maguire, Aoife ^a   Sheahan, Kieran ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Colorectal cancer; Histopathology; Prognosis; Staging; Tumor node metastasis

Indexed keywords

B RAF KINASE; CD31 ANTIGEN; CD34 ANTIGEN; CYTOKERATIN; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4, 5 BISPHOSPHATE 3 KINASE; UNCLASSIFIED DRUG; TUMOR MARKER;

CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; COLORECTAL CANCER; FIBROSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LYMPH NODE METASTASIS; META ANALYSIS (TOPIC); MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PERINEURAL INVASION; PERITONEUM CANCER; REPRODUCIBILITY; REVIEW; SCAR; STROMA; SYSTEMATIC REVIEW (TOPIC); TUMOR GRADE; TUMOR INVASION; TUMOR REGRESSION; ULCER; VASCULAR INVASION; ANIMAL; BLOOD VESSEL; CANCER GRADING; COLORECTAL TUMOR; GENETICS; LYMPH NODE; METABOLISM; PATHOLOGY; PERIPHERAL NERVE; PERITONEUM; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; ANGIOGENESIS; ARTICLE; BASEMENT MEMBRANE; CANCER CELL; CANCER REGRESSION; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; INFLAMMATORY CELL; OVERALL SURVIVAL; PREDICTION; TUMOR DIFFERENTIATION;

ANIMALS; BLOOD VESSELS; COLORECTAL NEOPLASMS; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PERIPHERAL NERVES; PERITONEUM; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84905841369     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i29.9850     Document Type: Review

References (121)

1. Sobin LH, Gospodarowic MK, Wittekind C, editors. International Union Against Cancer (UICC). TNM classification of malignant tumours. 7th ed. New York: Wiley-Blackwell, 2009
2. Puppa G, Sonzogni A, Colombari R, Pelosi G. TNM staging system of colorectal carcinoma: a critical appraisal of challenging issues. Arch Pathol Lab Med 2010; 134: 837-852 [PMID: 20524862 DOI: 10.1043/1543-2165-134.6.837]
3. Lennon AM, Mulcahy HE, Hyland JM, Lowry C, White A, Fennelly D, Murphy JJ, O'Donoghue DP, Sheahan K. Peritoneal involvement in stage II colon cancer. Am J Clin Pathol 2003; 119: 108-113 [PMID: 12520705 DOI: 10.1309/J6BDTWM2M792TN2V]
4. Ludeman L, Shepherd NA. Serosal involvement in gastrointestinal cancer: its assessment and significance. Histopathology 2005; 47: 123-131 [PMID: 16045772 DOI: 10.1111/j.1365-2559.2005.02189.x]
5. Shepherd NA, Baxter KJ, Love SB. The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation. Gastroenterology 1997; 112: 1096-1102 [PMID: 9097991]
6. Kojima M, Nakajima K, Ishii G, Saito N, Ochiai A. Peritoneal elastic laminal invasion of colorectal cancer: the diagnostic utility and clinicopathologic relationship. Am J Surg Pathol 2010; 34: 1351-1360 [PMID: 20716999 DOI: 10.1097/PAS.0b013e3181ecfe98]
7. Mitchard JR, Love SB, Baxter KJ, Shepherd NA. How important is peritoneal involvement in rectal cancer? A prospective study of 331 cases. Histopathology 2010; 57: 671-679 [PMID: 21083598 DOI: 10.1111/j.1365-2559.2010.03687.x]
8. Williams GT, Quirke P, Shepherd NA. Dataset for Colorectal Cancer. 2nd ed. London: The Royal College of Pathologists, 2007
9. Sobin LH, Wittekind CH, editors. International Union Against Cancer (UICC). TNM classification of malignant tumours. 5th ed. New York: Wiley-Liss Publications, 1997
10. Burdy G, Panis Y, Alves A, Nemeth J, Lavergne-Slove A, Valleur P. Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 2001; 44: 1682-1688 [PMID: 11711742 DOI: 10.1007/BF02234390]
11. Merkel S, Wein A, Günther K, Papadopoulos T, Hohenberger W, Hermanek P. High-risk groups of patients with Stage II colon carcinoma. Cancer 2001; 92: 1435-1443 [PMID: 11745220]
12. Morris M, Platell C, de Boer B, McCaul K, Iacopetta B. Population-based study of prognostic factors in stage II colonic cancer. Br J Surg 2006; 93: 866-871 [PMID: 16622901 DOI: 10.1002/bjs.5345]
13. Newland RC, Dent OF, Chapuis PH, Bokey L. Survival after curative resection of lymph node negative colorectal carcinoma. A prospective study of 910 patients. Cancer 1995; 76: 564-571 [PMID: 8625148]
14. Petersen VC, Baxter KJ, Love SB, Shepherd NA. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 2002; 51: 65-69 [PMID: 12077094 DOI: 10.1136/gut.51.1.65]
15. Grin A, Messenger DE, Cook M, O'Connor BI, Hafezi S, El-Zimaity H, Kirsch R. Peritoneal elastic lamina invasion: limitations in its use as a prognostic marker in stage II colorectal cancer. Hum Pathol 2013; 44: 2696-2705 [PMID: 24074534 DOI: 10.1016/j.humpath.2013.07.013]
16. Stewart CJ, Hillery S, Platell C, Puppa G. Assessment of Serosal Invasion and Criteria for the Classification of Pathological (p) T4 Staging in Colorectal Carcinoma: Confusions, Controversies and Criticisms. Cancers (Basel) 2011; 3: 164-181 [PMID: 24212611 DOI: 10.3390/cancers3010164]
17. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. Colon and Rectum. AJCC Cancer Staging Manual. 7th ed. New York: Springer, 2010
18. Shepherd NA, Baxter KJ, Love SB. Influence of local peritoneal involvement on pelvic recurrence and prognosis in rectal cancer. J Clin Pathol 1995; 48: 849-855 [PMID: 7490320 DOI: 10.1136/jcp.48.9.849]
19. Canney AL, Kevans D, Wang LM, Hyland JM, Mulcahy HE, O'Donoghue DP, O'Sullivan J, Geraghty R, Sheahan K. Stage II colonic adenocarcinoma: a detailed study of pT4N0 with emphasis on peritoneal involvement and the role of tumour budding. Histopathology 2012; 61: 488-496 [PMID: 22463746 DOI: 10.1111/j.1365-2559.2012.04250.x]
20. Panarelli NC, Schreiner AM, Brandt SM, Shepherd NA, Yantiss RK. Histologic features and cytologic techniques that aid pathologic stage assessment of colonic adenocarcinoma. Am J Surg Pathol 2013; 37: 1252-1258 [PMID: 23774176 DOI: 10.1097/PAS.0b013e3182960e7c]
21. Puppa G, Shepherd NA, Sheahan K, Stewart CJ. Peritoneal elastic lamina invasion in colorectal cancer: the answer to a controversial area of pathology? Am J Surg Pathol 2011; 35: 465-468; author reply 468-469 [PMID: 21317719 DOI: 10.1097/PAS.0b013e31820ac84a]
22. Stewart C, Hillery S, Havlat M. Serosal involvement in colorectal carcinoma. Histopathology 2006; 49: 435-437 [PMID: 16978212 DOI: 10.1111/j.1365-2559.2006.02498.x]
23. Zeng Z, Cohen AM, Hajdu S, Sternberg SS, Sigurdson ER, Enker W. Serosal cytologic study to determine free mesothelial penetration of intraperitoneal colon cancer. Cancer 1992; 70: 737-740 [PMID: 1643606]
24. Liang WY, Chang WC, Hsu CY, Arnason T, Berger D, Hawkins AT, Sylla P, Lauwers GY. Retrospective evaluation of elastic stain in the assessment of serosal invasion of pT3N0 colorectal cancers. Am J Surg Pathol 2013; 37: 1565-1570 [PMID: 23774172 DOI: 10.1097/PAS.0b013e31828ea2de]
25. Shinto E, Ueno H, Hashiguchi Y, Hase K, Tsuda H, Matsubara O, Mochizuki H. The subserosal elastic lamina: an anatomic landmark for stratifying pT3 colorectal cancer. Dis Colon Rectum 2004; 47: 467-473 [PMID: 14994112 DOI: 10.1007/s10350-003-0083-9]
26. Nagtegaal ID, Quirke P. Colorectal tumour deposits in the mesorectum and pericolon; a critical review. Histopathology 2007; 51: 141-149 [PMID: 17532768 DOI: 10.1111/j.1365-2559.2007.02720.x]
27. Belt EJ, van Stijn MF, Bril H, de Lange-de Klerk ES, Meijer GA, Meijer S, Stockmann HB. Lymph node negative colorectal cancers with isolated tumor deposits should be classified and treated as stage III. Ann Surg Oncol 2010; 17: 3203-3211 [PMID: 20625841 DOI: 10.1245/s10434-010-1152-7]
28. Puppa G, Maisonneuve P, Sonzogni A, Masullo M, Capelli P, Chilosi M, Menestrina F, Viale G, Pelosi G. Pathological assessment of pericolonic tumor deposits in advanced colonic carcinoma: relevance to prognosis and tumor staging. Mod Pathol 2007; 20: 843-855 [PMID: 17491597 DOI: 10.1038/modpathol.3800791]
29. Goldstein NS, Turner JR. Pericolonic tumor deposits in patients with T3N+MO colon adenocarcinomas: markers of reduced disease free survival and intra-abdominal metastases and their implications for TNM classification. Cancer 2000; 88: 2228-2238 [PMID: 10820343 DOI: 10.1002/(SICI)1097-0142(20000515)88:10〈2228::AID-CNCR5〉3.3.CO;2-T]
30. Wünsch K, Müller J, Jähnig H, Herrmann RA, Arnholdt HM, Märkl B. Shape is not associated with the origin of pericolonic tumor deposits. Am J Clin Pathol 2010; 133: 388-394 [PMID: 20154277 DOI: 10.1309/AJCPAWOLX7ADZQ2K]
31. Puppa G. TNM staging system of colorectal carcinoma: surgical pathology of the seventh edition. Diag Histopathol 2011; 17: 243-262 [DOI: 10.1016/j.mpdhp.2011.03.006]
32. Sobin LH, Wittekind CH, editors. International Union Against Cancer (UICC). TNM classification of malignant tumours. 6th ed. New York: Wiley-LIss Publications, 2002
33. Beattie GC, McAdam TK, Elliott S, Sloan JM, Irwin ST. Improvement in quality of colorectal cancer pathology reporting with a standardized proforma - a comparative study. Colorectal Dis 2003; 5: 558-562 [PMID: 14617240 DOI: 10.1046/j.1463-1318.2003.00466.x]
34. Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg 2002; 236: 416-421; discussion 421 [PMID: 12368669 DOI: 10.1097/00000658-200210000-00003]
35. Freedman LS, Macaskill P, Smith AN. Multivariate analysis of prognostic factors for operable rectal cancer. Lancet 1984; 2: 733-736 [PMID: 6148482 DOI: 10.1016/S0140-6736(84)92636-9]
36. Bruckner HW, Pitrelli J, Merrick M. Carcinoma of the colon and rectum. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO Classification of Tumours of the Digestive System. Lyon: IARC Press, 2010: 138-139
37. Compton CC. Optimal pathologic staging: defining stage II disease. Clin Cancer Res 2007; 13: 6862s-6870s [PMID: 18006791]
38. Ueno H, Kajiwara Y, Shimazaki H, Shinto E, Hashiguchi Y, Nakanishi K, Maekawa K, Katsurada Y, Nakamura T, Mochizuki H, Yamamoto J, Hase K. New criteria for histologic grading of colorectal cancer. Am J Surg Pathol 2012; 36: 193-201 [PMID: 22251938 DOI: 10.1097/PAS.0b013e318235edee]
39. Barresi V, Reggiani Bonetti L, Branca G, Di Gregorio C, Ponz de Leon M, Tuccari G. Colorectal carcinoma grading by quantifying poorly differentiated cell clusters is more reproducible and provides more robust prognostic information than conventional grading. Virchows Arch 2012; 461: 621-628 [PMID: 23093109 DOI: 10.1007/s00428-012-1326-8]
40. Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007; 50: 151-162 [PMID: 17204028 DOI: 10.1111/j.1365-2559.2006.02551.x]
41. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003; 3: 362-374 [PMID: 12724734 DOI: 10.1038/nrc1075]
42. Lugli A, Karamitopoulou E, Zlobec I. Tumour budding: a promising parameter in colorectal cancer. Br J Cancer 2012; 106: 1713-1717 [PMID: 22531633 DOI: 10.1038/bjc.2012.127]
43. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010; 1: 651-661 [PMID: 21317460]
44. Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol 2012; 25: 1315-1325 [PMID: 22790014 DOI: 10.1038/modpathol.2012.94]
45. Wang LM, Kevans D, Mulcahy H, O'Sullivan J, Fennelly D, Hyland J, O'Donoghue D, Sheahan K. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol 2009; 33: 134-141 [PMID: 18971777 DOI: 10.1097/PAS.0b013e318184cd55]
46. Choi HJ, Park KJ, Shin JS, Roh MS, Kwon HC, Lee HS. Tumor budding as a prognostic marker in stage-III rectal carcinoma. Int J Colorectal Dis 2007; 22: 863-868 [PMID: 17216219 DOI: 10.1007/s00384-006-0249-8]
47. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum 1993; 36: 627-635 [PMID: 8348847 DOI: 10.1007/BF02238588]
48. Tanaka M, Hashiguchi Y, Ueno H, Hase K, Mochizuki H. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum 2003; 46: 1054-1059 [PMID: 12907899 DOI: 10.1007/s10350-004-7280-z]
49. Okuyama T, Nakamura T, Yamaguchi M. Budding is useful to select high-risk patients in stage II well-differentiated or moderately differentiated colon adenocarcinoma. Dis Colon Rectum 2003; 46: 1400-1406 [PMID: 14530682 DOI: 10.1007/s10350-004-6757-0]
50. Nakamura T, Mitomi H, Kikuchi S, Ohtani Y, Sato K. Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer. Hepatogastroenterology 2005; 52: 1432-1435 [PMID: 16201089]
51. Ueno H, Mochizuki H, Hashiguchi Y, Shimazaki H, Aida S, Hase K, Matsukuma S, Kanai T, Kurihara H, Ozawa K, Yoshimura K, Bekku S. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004; 127: 385-394 [PMID: 15300569 DOI: 10.1053/j.gastro.2004.04.022]
52. Choi DH, Sohn DK, Chang HJ, Lim SB, Choi HS, Jeong SY. Indications for subsequent surgery after endoscopic resection of submucosally invasive colorectal carcinomas: a prospective cohort study. Dis Colon Rectum 2009; 52: 438-445 [PMID: 19333043 DOI: 10.1007/DCR.0b013e318197e37f]
53. Park KJ, Choi HJ, Roh MS, Kwon HC, Kim C. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum 2005; 48: 1597-1602 [PMID: 15937624 DOI: 10.1007/s10350-005-0060-6]
54. Tateishi Y, Nakanishi Y, Taniguchi H, Shimoda T, Umemura S. Pathological prognostic factors predicting lymph node metastasis in submucosal invasive (T1) colorectal carcinoma. Mod Pathol 2010; 23: 1068-1072 [PMID: 20473277 DOI: 10.1038/modpathol.2010.88]
55. Kye BH, Jung JH, Kim HJ, Kang SG, Cho HM, Kim JG. Tumor budding as a risk factor of lymph node metastasis in submucosal invasive T1 colorectal carcinoma: a retrospective study. BMC Surg 2012; 12: 16 [PMID: 22866826 DOI: 10.1186/1471-2482-12-16]
56. Rogers AC, Gibbons D, Hanly AM, Hyland JM, O'Connell PR, Winter DC, Sheahan K. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Mod Pathol 2014; 27: 156-162 [PMID: 23887296 DOI: 10.1038/modpathol.2013.124]
57. Giger OT, Comtesse SC, Lugli A, Zlobec I, Kurrer MO. Intratumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer. Mod Pathol 2012; 25: 1048-1053 [PMID: 22481282 DOI: 10.1038/modpathol.2012.56]
58. Horcic M, Koelzer VH, Karamitopoulou E, Terracciano L, Puppa G, Zlobec I, Lugli A. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol 2013; 44: 697-705 [PMID: 23159156 DOI: 10.1016/j.humpath.2012.07.026]
59. Puppa G, Senore C, Sheahan K, Vieth M, Lugli A, Zlobec I, Pecori S, Wang LM, Langner C, Mitomi H, Nakamura T, Watanabe M, Ueno H, Chasle J, Conley SA, Herlin P, Lauwers GY, Risio M. Diagnostic reproducibility of tumour budding in colorectal cancer: a multicentre, multinational study using virtual microscopy. Histopathology 2012; 61: 562-575 [PMID: 22765314 DOI: 10.1111/j.1365-2559.2012.04270.x]
60. Washington MK. Colorectal carcinoma: selected issues in pathologic examination and staging and determination of prognostic factors. Arch Pathol Lab Med 2008; 132: 1600-1607 [PMID: 18834218]
61. Talbot IC, Ritchie S, Leighton MH, Hughes AO, Bussey HJ, Morson BC. The clinical significance of invasion of veins by rectal cancer. Br J Surg 1980; 67: 439-442 [PMID: 7388345]
62. Sternberg A, Amar M, Alfici R, Groisman G. Conclusions from a study of venous invasion in stage IV colorectal adenocarcinoma. J Clin Pathol 2002; 55: 17-21 [PMID: 11825918]
63. Desolneux G, Burtin P, Lermite E, Bergamaschi R, Hamy A, Arnaud JP. Prognostic factors in node-negative colorectal cancer: a retrospective study from a prospective database. Int J Colorectal Dis 2010; 25: 829-834 [PMID: 20405293 DOI: 10.1007/s00384-010-0934-5]
64. Betge J, Pollheimer MJ, Lindtner RA, Kornprat P, Schlemmer A, Rehak P, Vieth M, Hoefler G, Langner C. Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. Cancer 2012; 118: 628-638 [PMID: 21751188 DOI: 10.1002/cncr.26310]
65. Suzuki A, Togashi K, Nokubi M, Koinuma K, Miyakura Y, Horie H, Lefor AT, Yasuda Y. Evaluation of venous invasion by Elastica van Gieson stain and tumor budding predicts local and distant metastases in patients with T1 stage colorectal cancer. Am J Surg Pathol 2009; 33: 1601-1607 [PMID: 19574884 DOI: 10.1097/PAS.0b013e3181ae29d6]
66. Sejben I, Bori R, Cserni G. Venous invasion demonstrated by orcein staining of colorectal carcinoma specimens is associated with the development of distant metastasis. J Clin Pathol 2010; 63: 575-578 [PMID: 20501452 DOI: 10.1136/jcp.2010.075846]
67. Brown CF, Warren S. Visceral metastasis from rectal carcinoma. Surg Gynecol Obstet 1938; 66: 611-621
68. Liang P, Nakada I, Hong JW, Tabuchi T, Motohashi G, Takemura A, Nakachi T, Kasuga T, Tabuchi T. Prognostic significance of immunohistochemically detected blood and lymphatic vessel invasion in colorectal carcinoma: its impact on prognosis. Ann Surg Oncol 2007; 14: 470-477 [PMID: 17103258]
69. Glasgow SC, Bleier JI, Burgart LJ, Finne CO, Lowry AC. Meta-analysis of histopathological features of primary colorectal cancers that predict lymph node metastases. J Gastrointest Surg 2012; 16: 1019-1028 [PMID: 22258880 DOI: 10.1007/s11605-012-1827-4]
70. Akagi Y, Adachi Y, Ohchi T, Kinugasa T, Shirouzu K. Prognostic impact of lymphatic invasion of colorectal cancer: a single-center analysis of 1,616 patients over 24 years. Anticancer Res 2013; 33: 2965-2970 [PMID: 23780987]
71. Talbot IC, Ritchie S, Leighton MH, Hughes AO, Bussey HJ, Morson BC. Spread of rectal cancer within veins. Histologic features and clinical significance. Am J Surg 1981; 141: 15-17 [PMID: 7457719 DOI: 10.1016/0002-9610(81)90004-0]
72. Kojima M, Shimazaki H, Iwaya K, Kage M, Akiba J, Ohkura Y, Horiguchi S, Shomori K, Kushima R, Ajioka Y, Nomura S, Ochiai A. Pathological diagnostic criterion of blood and lymphatic vessel invasion in colorectal cancer: a framework for developing an objective pathological diagnostic system using the Delphi method, from the Pathology Working Group of the Japanese Society for Cancer of the Colon and Rectum. J Clin Pathol 2013; 66: 551-558 [PMID: 23592799 DOI: 10.1136/jclinpath-2012-201076]
73. Messenger DE, Driman DK, McLeod RS, Riddell RH, Kirsch R. Current practice patterns among pathologists in the assessment of venous invasion in colorectal cancer. J Clin Pathol 2011; 64: 983-989 [PMID: 21697290 DOI: 10.1136/jclinpath-2011-200156]
74. Harris EI, Lewin DN, Wang HL, Lauwers GY, Srivastava A, Shyr Y, Shakhtour B, Revetta F, Washington MK. Lymphovascular invasion in colorectal cancer: an interobserver variability study. Am J Surg Pathol 2008; 32: 1816-1821 [PMID: 18779725 DOI: 10.1097/PAS.0b013e3181816083]
75. Littleford SE, Baird A, Rotimi O, Verbeke CS, Scott N. Interobserver variation in the reporting of local peritoneal involvement and extramural venous invasion in colonic cancer. Histopathology 2009; 55: 407-413 [PMID: 19817891 DOI: 10.1111/j.1365-2559.2009.03397.x]
76. Dirschmid K, Sterlacci W, Oellig F, Edlinger M, Jasarevic Z, Rhomberg M, Dirschmid H, Offner F. Absence of extramural venous invasion is an excellent predictor of metastasis-free survival in colorectal carcinoma stage II - a study using tangential tissue sectioning. J Clin Pathol 2012; 65: 619-623 [PMID: 22554966 DOI: 10.1136/jclinpath-2011-200552]
77. Kirsch R, Messenger DE, Riddell RH, Pollett A, Cook M, Al-Haddad S, Streutker CJ, Divaris DX, Pandit R, Newell KJ, Liu J, Price RG, Smith S, Parfitt JR, Driman DK. Venous invasion in colorectal cancer: impact of an elastin stain on detection and interobserver agreement among gastrointestinal and nongastrointestinal pathologists. Am J Surg Pathol 2013; 37: 200-210 [PMID: 23108018 DOI: 10.1097/PAS.0b013e31826a92cd]
78. Vass DG, Ainsworth R, Anderson JH, Murray D, Foulis AK. The value of an elastic tissue stain in detecting venous invasion in colorectal cancer. J Clin Pathol 2004; 57: 769-772 [PMID: 15220375]
79. Messenger DE, Driman DK, Kirsch R. Developments in the assessment of venous invasion in colorectal cancer: implications for future practice and patient outcome. Hum Pathol 2012; 43: 965-973 [PMID: 22406362 DOI: 10.1016/j.humpath.2011.11.015]
80. Howlett CJ, Tweedie EJ, Driman DK. Use of an elastic stain to show venous invasion in colorectal carcinoma: a simple technique for detection of an important prognostic factor. J Clin Pathol 2009; 62: 1021-1025 [PMID: 19861561 DOI: 10.1136/jcp.2009.065615]
81. Kingston EF, Goulding H, Bateman AC. Vascular invasion is underrecognized in colorectal cancer using conventional hematoxylin and eosin staining. Dis Colon Rectum 2007; 50: 1867-1872 [PMID: 17665249]
82. Cserni G, Sejben I, Bori R. Diagnosing vascular invasion in colorectal carcinomas: improving reproducibility and potential pitfalls. J Clin Pathol 2013; 66: 543-547 [PMID: 23592798 DOI: 10.1136/jclinpath-2013-201587]
83. Liebig C, Ayala G, Wilks J, Verstovsek G, Liu H, Agarwal N, Berger DH, Albo D. Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol 2009; 27: 5131-5137 [PMID: 19738119 DOI: 10.1200/JCO.2009.22.4949]
84. Fujita S, Shimoda T, Yoshimura K, Yamamoto S, Akasu T, Moriya Y. Prospective evaluation of prognostic factors in patients with colorectal cancer undergoing curative resection. J Surg Oncol 2003; 84: 127-131 [PMID: 14598355 DOI: 10.1002/jso.10308]
85. Poeschl EM, Pollheimer MJ, Kornprat P, Lindtner RA, Schlemmer A, Rehak P, Vieth M, Langner C. Perineural invasion: correlation with aggressive phenotype and independent prognostic variable in both colon and rectum cancer. J Clin Oncol 2010; 28: e358-e360; author reply e361-e362 [PMID: 20385977 DOI: 10.1200/JCO.2009.27.3581]
86. Peng J, Sheng W, Huang D, Venook AP, Xu Y, Guan Z, Cai S. Perineural invasion in pT3N0 rectal cancer: the incidence and its prognostic effect. Cancer 2011; 117: 1415-1421 [PMID: 21425141 DOI: 10.1002/cncr.25620]
87. Ueno H, Shirouzu K, Eishi Y, Yamada K, Kusumi T, Kushima R, Ikegami M, Murata A, Okuno K, Sato T, Ajioka Y, Ochiai A, Shimazaki H, Nakamura T, Kawachi H, Kojima M, Akagi Y, Sugihara K. Characterization of perineural invasion as a component of colorectal cancer staging. Am J Surg Pathol 2013; 37: 1542-1549 [PMID: 24025524 DOI: 10.1097/PAS.0b013e318297ef6e]
88. Weiser MR, Landmann RG, Kattan MW, Gonen M, Shia J, Chou J, Paty PB, Guillem JG, Temple LK, Schrag D, Saltz LB, Wong WD. Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol 2008; 26: 380-385 [PMID: 18202413 DOI: 10.1200/JCO.2007.14.1291]
89. Liebl F, Demir IE, Rosenberg R, Boldis A, Yildiz E, Kujundzic K, Kehl T, Dischl D, Schuster T, Maak M, Becker K, Langer R, Laschinger M, Friess H, Ceyhan GO. The severity of neural invasion is associated with shortened survival in colon cancer. Clin Cancer Res 2013; 19: 50-61 [PMID: 23147996 DOI: 10.1158/1078-0432.CCR-12-2392]
90. Wang LM, Sheahan, K. Prognostic markers in colorectal pathology: Is morphology enough? Diag Histopathol 2011; 17: 386-394 [DOI: 10.1016/j.mpdhp.2011.06.016]
91. Batsakis JG. Nerves and neurotropic carcinomas. Ann Otol Rhinol Laryngol 1985; 94: 426-427 [PMID: 4026129]
92. Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer: a review of the literature. Cancer 2009; 115: 3379-3391 [PMID: 19484787 DOI: 10.1002/cncr.24396]
93. Ceyhan GO, Liebl F, Maak M, Schuster T, Becker K, Langer R, Demir IE, Hartel M, Friess H, Rosenberg R. The severity of neural invasion is a crucial prognostic factor in rectal cancer independent of neoadjuvant radiochemotherapy. Ann Surg 2010; 252: 797-804 [PMID: 21037435 DOI: 10.1097/SLA.0b013e3181fcab8d]
94. Resch A, Langner C. Lymph node staging in colorectal cancer: old controversies and recent advances. World J Gastroenterol 2013; 19: 8515-8526 [PMID: 24379568 DOI: 10.3748/wjg.v19.i46.8515]
95. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007; 99: 433-441 [PMID: 17374833 DOI: 10.1093/jnci/djk092]
96. Moore J, Hyman N, Callas P, Littenberg B. Staging error does not explain the relationship between the number of lymph nodes in a colon cancer specimen and survival. Surgery 2010; 147: 358-365 [PMID: 19962166 DOI: 10.1016/j.surg.2009.10.003]
97. Chandrasinghe PC, Ediriweera DS, Hewavisenthi J, Kumarage S, Deen KI. The total number of lymph nodes harvested is associated with better survival in stages II and III colorectal cancer. Indian J Gastroenterol 2014; 33: 249-253 [PMID: 24048680 DOI: 10.1007/s12664-013-0406-2]
98. Johnson PM, Malatjalian D, Porter GA. Adequacy of nodal harvest in colorectal cancer: a consecutive cohort study. J Gastrointest Surg 2002; 6: 883-888; discussion 889-890 [PMID: 12504228 DOI: 10.1016/S1091-255X(02)00131-2]
99. Chou JF, Row D, Gonen M, Liu YH, Schrag D, Weiser MR. Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study. Cancer 2010; 116: 2560-2570 [PMID: 20499400 DOI: 10.1002/cncr.25032]
100. Brown HG, Luckasevic TM, Medich DS, Celebrezze JP, Jones SM. Efficacy of manual dissection of lymph nodes in colon cancer resections. Mod Pathol 2004; 17: 402-406 [PMID: 14976530 DOI: 10.1038/modpathol.3800071]
101. Kim YM, Suh JH, Cha HJ, Jang SJ, Kim MJ, Yoon S, Kim B, Chang H, Kwon Y, Hong EK, Ro JY. Additional lymph node examination from entire submission of residual mesenteric tissue in colorectal cancer specimens may not add clinical and pathologic relevance. Hum Pathol 2007; 38: 762-767 [PMID: 17306331 DOI: 10.1016/j.humpath.2006.11.005]
102. Abbassi-Ghadi N, Boshier PR, Goldin R, Hanna GB. Techniques to increase lymph node harvest from gastrointestinal cancer specimens: a systematic review and meta-analysis. Histopathology 2012; 61: 531-542 [PMID: 23551433 DOI: 10.1111/j.1365-2559.2012.04357.x]
103. Wang LM, Sheahan K. Pathological assessment of post-treatment gastrointestinal and hepatic resection specimens. Cur Diag Pathol 2007; 13: 222-231 [DOI: 10.1016/j.cdip.2007.04.006]
104. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-2686 [PMID: 8194005]
105. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12: 19-23 [PMID: 9112145 DOI: 10.1007/s003840050072]
106. Beddy D, Hyland JM, Winter DC, Lim C, White A, Moriarty M, Armstrong J, Fennelly D, Gibbons D, Sheahan K. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy. Ann Surg Oncol 2008; 15: 3471-3477 [PMID: 18846402 DOI: 10.1245/s10434-008-0149-y]
107. Wheeler JM, Warren BF, Mortensen NJ, Ekanyaka N, Kulacoglu H, Jones AC, George BD, Kettlewell MG. Quantification of histologic regression of rectal cancer after irradiation: a proposal for a modified staging system. Dis Colon Rectum 2002; 45: 1051-1056 [PMID: 12195189 DOI: 10.1007/s10350-004-6359-x]
108. Janjan NA, Khoo VS, Abbruzzese J, Pazdur R, Dubrow R, Cleary KR, Allen PK, Lynch PM, Glober G, Wolff R, Rich TA, Skibber J. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 1999; 44: 1027-1038 [PMID: 10421535 DOI: 10.1016/S0360-3016(99)00099-1]
109. Pucciarelli S, Toppan P, Friso ML, Russo V, Pasetto L, Urso E, Marino F, Ambrosi A, Lise M. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum 2004; 47: 1798-1807 [PMID: 15622571 DOI: 10.1007/s10350-004-0681-1]
110. Vecchio FM, Valentini V, Minsky BD, Padula GD, Venkatraman ES, Balducci M, Miccichè F, Ricci R, Morganti AG, Gambacorta MA, Maurizi F, Coco C. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 2005; 62: 752-760 [PMID: 15936556 DOI: 10.1016/j.ijrobp.2004.11.017]
111. Valentini V, Coco C, Cellini N, Picciocchi A, Fares MC, Rosetto ME, Mantini G, Morganti AG, Barbaro B, Cogliandolo S, Nuzzo G, Tedesco M, Ambesi-Impiombato F, Cosimelli M, Rotman M. Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies. Int J Radiat Oncol Biol Phys 2001; 51: 371-383 [PMID: 11567811]
112. Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, Calvo FA, García-Aguilar J, Glynne-Jones R, Haustermans K, Mohiuddin M, Pucciarelli S, Small W, Suárez J, Theodoropoulos G, Biondo S, Beets-Tan RG, Beets GL. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11: 835-844 [PMID: 20692872 DOI: 10.1016/S1470-2045(10)70172-8]
113. Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, Quirke P, Sebag-Montefiore D, Moran B, Heald R, Guthrie A, Bees N, Swift I, Pennert K, Brown G. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011; 29: 3753-3760 [PMID: 21876084 DOI: 10.1200/JCO.2011.34.9068]
114. Min BS, Kim NK, Pyo JY, Kim H, Seong J, Keum KC, Sohn SK, Cho CH. Clinical impact of tumor regression grade after preoperative chemoradiation for locally advanced rectal cancer: subset analyses in lymph node negative patients. J Korean Soc Coloproctol 2011; 27: 31-40 [PMID: 21431095 DOI: 10.3393/jksc.2011.27.1.31]
115. Lin CY, Tian YF, Wu LC, Chen LT, Lin LC, Hsing CH, Lee SW, Sheu MJ, Lee HH, Wang YH, Shiue YL, Wu WR, Huang HY, Hsu HP, Li CF, Chen SH. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation. J Clin Pathol 2012; 65: 687-692 [PMID: 22569540 DOI: 10.1136/jclinpath- 2012-200786]
116. MacGregor TP, Maughan TS, Sharma RA. Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now. J Clin Pathol 2012; 65: 867-871 [PMID: 22734005]
117. Chetty R, Gill P, Govender D, Bateman A, Chang HJ, Driman D, Duthie F, Gomez M, Jaynes E, Lee CS, Locketz M, Mescoli C, Rowsell C, Rullier A, Serra S, Shepherd N, Szentgyorgyi E, Vajpeyi R, Wang LM. A multi-centre pathologist survey on pathological processing and regression grading of colorectal cancer resection specimens treated by neoadjuvant chemoradiation. Virchows Arch 2012; 460: 151-155 [PMID: 22241181 DOI: 10.1007/s00428-012-1193-3]
118. Chetty R, Gill P, Govender D, Bateman A, Chang HJ, Deshpande V, Driman D, Gomez M, Greywoode G, Jaynes E, Lee CS, Locketz M, Rowsell C, Rullier A, Serra S, Shepherd N, Szentgyorgyi E, Vajpeyi R, Wang LM, Bateman A. International study group on rectal cancer regression grading: interobserver variability with commonly used regression grading systems. Hum Pathol 2012; 43: 1917-1923 [PMID: 22575264 DOI: 10.1016/j.humpath.2012.01.020]
119. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765 [PMID: 18946061 DOI: 10.1056/NEJMoa0804385]
120. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367: 1596-1606 [PMID: 23094721 DOI: 10.1056/NEJMoa1207756]
121. Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011; 9 Suppl 5: S1-S32; quiz S33 [PMID: 22138009]